Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. / Cele, Sandile; Network for Genomic Surveillance in South Africa; COMMIT-KZN Team.
In: Nature, Vol. 593, No. 7857, 2021, p. 142-146.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
AU - Cele, Sandile
AU - Gazy, Inbal
AU - Jackson, Laurelle
AU - Hwa, Shi Hsia
AU - Tegally, Houriiyah
AU - Lustig, Gila
AU - Giandhari, Jennifer
AU - Pillay, Sureshnee
AU - Wilkinson, Eduan
AU - Naidoo, Yeshnee
AU - Karim, Farina
AU - Ganga, Yashica
AU - Khan, Khadija
AU - Bernstein, Mallory
AU - Balazs, Alejandro B.
AU - Gosnell, Bernadett I.
AU - Hanekom, Willem
AU - Moosa, Mahomed Yunus S.
AU - Abrahams, Shareef
AU - Alcantara, Luiz Carlos Junior
AU - Alisoltani-Dehkordi, Arghavan
AU - Allam, Mushal
AU - Bhiman, Jinal N.
AU - Davies, Mary Ann
AU - Doolabh, Deelan
AU - Engelbrecht, Susan
AU - Fonseca, Vagner
AU - Giovanetti, Marta
AU - Glass, Allison J.
AU - Godzik, Adam
AU - Goedhals, Dominique
AU - Hardie, Diana
AU - Hsiao, Marvin
AU - Iranzadeh, Arash
AU - Ismail, Arshad
AU - Korsman, Stephen
AU - Pond, Sergei L.Kosakovsky
AU - Laguda-Akingba, Oluwakemi
AU - Lourenco, Jose
AU - Marais, Gert
AU - Martin, Darren
AU - Maslo, Caroline
AU - Mlisana, Koleka
AU - Mohale, Thabo
AU - Msomi, Nokukhanya
AU - Mudau, Innocent
AU - Petruccione, Francesco
AU - Preiser, Wolfgang
AU - San, Emmanuel James
AU - Kløverpris, Henrik
AU - Network for Genomic Surveillance in South Africa
AU - COMMIT-KZN Team
N1 - Publisher Copyright: © 2021, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021
Y1 - 2021
N2 - SARS-CoV-2 variants of concern (VOC) have arisen independently at multiple locations1,2 and may reduce the efficacy of current vaccines that target the spike glycoprotein of SARS-CoV-23. Here, using a live-virus neutralization assay, we compared the neutralization of a non-VOC variant with the 501Y.V2 VOC (also known as B.1.351) using plasma collected from adults who were hospitalized with COVID-19 during the two waves of infection in South Africa, the second wave of which was dominated by infections with the 501Y.V2 variant. Sequencing demonstrated that infections of plasma donors from the first wave were with viruses that did not contain the mutations associated with 501Y.V2, except for one infection that contained the E484K substitution in the receptor-binding domain. The 501Y.V2 virus variant was effectively neutralized by plasma from individuals who were infected during the second wave. The first-wave virus variant was effectively neutralized by plasma from first-wave infections. However, the 501Y.V2 variant was poorly cross-neutralized by plasma from individuals with first-wave infections; the efficacy was reduced by 15.1-fold relative to neutralization of 501Y.V2 by plasma from individuals infected in the second wave. By contrast, cross-neutralization of first-wave virus variants using plasma from individuals with second-wave infections was more effective, showing only a 2.3-fold decrease relative to neutralization of first-wave virus variants by plasma from individuals infected in the first wave. Although we tested only one plasma sample from an individual infected with a SARS-CoV-2 variant with only the E484K substitution, this plasma sample potently neutralized both variants. The observed effective neutralization of first-wave virus by plasma from individuals infected with 501Y.V2 provides preliminary evidence that vaccines based on VOC sequences could retain activity against other circulating SARS-CoV-2 lineages.
AB - SARS-CoV-2 variants of concern (VOC) have arisen independently at multiple locations1,2 and may reduce the efficacy of current vaccines that target the spike glycoprotein of SARS-CoV-23. Here, using a live-virus neutralization assay, we compared the neutralization of a non-VOC variant with the 501Y.V2 VOC (also known as B.1.351) using plasma collected from adults who were hospitalized with COVID-19 during the two waves of infection in South Africa, the second wave of which was dominated by infections with the 501Y.V2 variant. Sequencing demonstrated that infections of plasma donors from the first wave were with viruses that did not contain the mutations associated with 501Y.V2, except for one infection that contained the E484K substitution in the receptor-binding domain. The 501Y.V2 virus variant was effectively neutralized by plasma from individuals who were infected during the second wave. The first-wave virus variant was effectively neutralized by plasma from first-wave infections. However, the 501Y.V2 variant was poorly cross-neutralized by plasma from individuals with first-wave infections; the efficacy was reduced by 15.1-fold relative to neutralization of 501Y.V2 by plasma from individuals infected in the second wave. By contrast, cross-neutralization of first-wave virus variants using plasma from individuals with second-wave infections was more effective, showing only a 2.3-fold decrease relative to neutralization of first-wave virus variants by plasma from individuals infected in the first wave. Although we tested only one plasma sample from an individual infected with a SARS-CoV-2 variant with only the E484K substitution, this plasma sample potently neutralized both variants. The observed effective neutralization of first-wave virus by plasma from individuals infected with 501Y.V2 provides preliminary evidence that vaccines based on VOC sequences could retain activity against other circulating SARS-CoV-2 lineages.
U2 - 10.1038/s41586-021-03471-w
DO - 10.1038/s41586-021-03471-w
M3 - Journal article
C2 - 33780970
AN - SCOPUS:85103385503
VL - 593
SP - 142
EP - 146
JO - Nature
JF - Nature
SN - 0028-0836
IS - 7857
ER -
ID: 262796214